证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 FDA 创新药审评政策再松绑，利好创新药板 块 增持（维持） [Table_Tag] [Table_Summary] 投资要点 《降息等多因素支持科研上游持续复 苏，重点推荐皓元医药、奥浦迈等》 2026-02-01 东吴证券研究所 1 / 24 请务必阅读正文之后的免责声明部分 2026 年 02 月 23 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 20% 23% 2025/2/24 2025/6/22 2025/10/18 2026/2/13 医药生物 沪深300 相关研究 《分子胶海外风起，国内管线蓄势破 局》 2026-02-09 ◼ 本周（2.9-2.13 号，下同）、年初至今 A 股医药指数涨幅分别为-0.8%、 2.4%，相对沪深 300 的超额收益分别为-1.2%、1.8%；本周、年初至今 恒生生物科技指数涨跌幅分别为 4.8%、12.5%，相对于恒生科技指数跑 赢 7.3%、18.0%；本周 ...

Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. reported a slight decline in revenue and net profit for the first half of 2025, while showing significant growth in cash flow from operating activities and a strong performance in its main business of biological products, particularly in the reproductive health sector [1][3]. Financial Performance - The company's operating income for the reporting period was approximately 1.29 billion yuan, a decrease of 0.51% compared to the same period last year [1]. - The net profit attributable to shareholders was approximately 366.52 million yuan, down 11.92% year-on-year [1]. - The net cash flow from operating activities increased by 53.75% to approximately 316.42 million yuan [1]. - Basic earnings per share decreased by 11.72% to 0.2191 yuan [1]. Asset and Equity Status - Total assets at the end of the reporting period were approximately 4.92 billion yuan, a decrease of 4.14% from the previous year [2]. - The net assets attributable to shareholders were approximately 3.97 billion yuan, down 3.73% year-on-year [2]. Shareholder Structure - The top shareholder, Song Lihua, holds 26.56% of the shares, followed by Song Liming with 6.87% [2]. - The company has not experienced any changes in its controlling shareholder during the reporting period [3]. Business Development and Strategy - The company has optimized its sales channels and marketing strategies in response to intensified industry competition and market demand fluctuations, resulting in a 7.49% year-on-year growth in its main business of biological products [3]. - Sales revenue from the injectable drug Trastuzumab "Ansaiting" increased by 298% year-on-year [3]. - The company signed a strategic cooperation framework agreement with Weisheng Pharmaceutical to collaborate on a growth hormone product, enhancing its market position in the pediatric growth sector [4]. R&D and Product Pipeline - The company is advancing its R&D capabilities, with several projects in various clinical trial phases, including the HuA21 project and AK2017 injection [6][10]. - The company has received approval for the launch of Acetate Atosiban Injection, expanding its product offerings in the peptide formulation sector [7]. - The company is also developing mRNA vaccines in collaboration with Afana, with progress in clinical trials for HPV-related conditions [8][9]. Production Capacity and Infrastructure - The company is constructing a new production base in the eastern region, with approximately 90,000 square meters of infrastructure completed [4]. - New production lines for growth hormone injections and Trastuzumab have received production licenses and are in the registration and review stages [4][6].